Skip to main content
Egetis Therapeutics logo

Egetis Therapeutics — Investor Relations & Filings

Ticker · EGTX ISIN · SE0003815604 LEI · 549300RZCKGWRUBPMY22 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2024-10-31 AGM Information
Country SE Sweden
Listing ST EGTX

About Egetis Therapeutics

https://www.egetis.com/

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.

Recent filings

Filing Released Lang Actions
Egetis’ Nomination Committee for the 2025 Annual General Meeting
AGM Information Classification · 90% confidence The document explicitly announces the composition of the Nomination Committee for the upcoming 2025 Annual General Meeting (AGM). It details the appointed members and their roles concerning proposals for the AGM (Board members, remuneration, auditors). This content directly relates to the preparatory and administrative aspects of the Annual General Meeting. While it mentions the AGM, it is not the AGM presentation itself (AGM-R), nor is it a proxy statement (PSI) or a general management announcement (MANG). It is a specific announcement regarding the committee responsible for nominations related to the AGM. Given the options, this is most closely related to the governance and preparatory materials for the AGM, but since there isn't a specific 'Nomination Committee Announcement' code, I must evaluate the closest fit. The content is about the structure and function leading up to the AGM. It is not a general regulatory filing (RNS) or a governance report (CGR). Since the core subject is the committee for the AGM, and the AGM itself is the event, AGM-R (AGM Information) is the most relevant category, as these committees are integral to the AGM process and materials. However, the document is a press release announcing the committee, not the meeting materials themselves. Given the definitions, AGM-R covers 'Presentations and materials shared during the Annual General Meeting (AGM)'. This announcement precedes the meeting. If we consider the closest fit among the provided options, it deals with AGM logistics. If this were a general announcement of a corporate event preparation, RNS might be considered, but the subject is too specific. I will classify this as AGM-R as it is directly about the AGM's preparatory body, assuming AGM-R encompasses key announcements leading up to the meeting, or RNS as a specific announcement. Given the specificity, and the fact that it is an announcement about an AGM component, AGM-R is the strongest thematic fit, although RNS is a possibility for an announcement that doesn't fit elsewhere. Since the content is entirely focused on the AGM's nomination process, AGM-R is chosen over the general RNS.
2024-10-31 English
Egetis valberedning utsedd inför årsstämman 2025
Governance Information Classification · 99% confidence The document is a press release from Egetis Therapeutics AB announcing the composition of the Nomination Committee (Valberedningen) appointed ahead of the 2025 Annual General Meeting (årsstämman 2025). This announcement concerns the process leading up to the AGM, specifically the committee responsible for proposing board members and remuneration. This falls under the scope of AGM-related information, but since it is an announcement about the committee formation rather than the meeting materials themselves or the voting results, it is most closely related to the general governance and meeting preparation process. However, given the specific options, 'AGM-R' (AGM Information) is the most appropriate fit as it directly relates to the upcoming Annual General Meeting procedures, even if it's a preparatory announcement. It is not a DEF 14A (Remuneration) as it's about the committee selection, not the final remuneration report itself, nor is it a DVA (Voting Results). It is a specific announcement related to the AGM process.
2024-10-31 Swedish
Change in the number of shares and votes in Egetis Therapeutics
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing a change in the total number of shares and votes in Egetis Therapeutics due to a directed share issuance. This falls under the category of share capital changes or new share issues, which is specifically covered by the 'SHA' (Share Issue/Capital Change) category.
2024-10-31 English
Ändring av antalet aktier och röster i Egetis Therapeutics
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement regarding a change in the number of shares and votes in Egetis Therapeutics AB due to a directed share issue. This type of regulatory disclosure, which details changes in capital structure and share counts, is classified as a Share Issue/Capital Change announcement.
2024-10-31 Swedish
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 99% confidence The document explicitly details changes in shareholding percentages and voting rights for a specific holder (Cetoros AB) in Egetis Therapeutics AB, noting the 'Reason for major shareholding notification' and providing 'Before' and 'After the transaction' figures, including the date of the change (31/10/2024). This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the filing code MRQ.
2024-10-31 English
Egetis Therapeutics publishes prospectus for admission to trading of shares on Nasdaq Stockholm
Report Publication Announcement Classification · 95% confidence The document is a press release announcing the publication and approval of a prospectus for the admission of new shares to trading on Nasdaq Stockholm following a directed share issuance. While it discusses share issuance, the primary purpose of this specific document is to announce the availability of the prospectus (a regulatory document) to the public. According to the 'Menu vs Meal' rule, an announcement regarding the publication of a report or prospectus is classified as a Report Publication Announcement (RPA).
2024-10-28 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.